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HIV-associated sensory neuropathy (HIV-SN) is cur-
rently the most common neurological complication of
chronic HIV infection and continues to substantially
affect patient quality of life. Mechanisms underlying the
neuronal damage and loss observed in sensory ganglia
of HIV-infected individuals have not been sufficiently
studied. The present study aimed to develop and char-
acterize a model of HIV-SN using SIV-infected CD8 T-
lymphocyte-depleted rhesus macaques (Macaca mu-
latta). Uninfected controls (n  5), SIV-infected CD8-
depleted (n  4), and SIV-infected non-CD8-depleted (n
 6) animals were used. Of the six non-CD8-depleted
animals, three were conventional progressors (pro-
gressing to AIDS>1 year after infection) and three were
rapid progressors (AIDS within 6 months). Dorsal root
ganglia (DRG) were examined for histological hall-
marks of HIV-SN, including satellitosis, presence of Na-
geotte nodules, and neuronophagia, as well as increased
numbers of CD68 macrophages and abundant viral
replication. In contrast to non-CD8-depleted animals,
which had mild to moderate DRG pathology, the CD8-
depleted SIV-infected animalshadmoderate to severeDRG
damage, with increased numbers of CD68 satellite cells.
Additionally, there was marked active viral replication in
the affected DRG. These findings confirm that many fea-
tures of HIV-SN can be recapitulated in the CD8-depleted
SIV-infected rhesus macaque model within a short time
frameand illustrate the importanceof thismodel for study
of sensory neuropathy. (Am J Pathol 2012, 180:1362–1369;
DOI: 10.1016/j.ajpath.2011.12.016)
1362Since the advent of antiretroviral therapy, many neurolog-
ical complications resulting from HIV infection, including
HIV-associated dementia, have declined.1 Abnormalities
of the peripheral nervous system (PNS), however, con-
tinue to be among the most common neurological com-
plications of HIV-1 infection and are still poorly under-
stood. Existing antiretroviral therapies have marginal
effect on the incidence or severity of HIV-associated sen-
sory neuropathy (HIV-SN),2–8 and HIV-SN continues to
substantially and negatively affect quality of life for chron-
ically HIV-infected patients. The pathogenesis of non–
drug-related toxicities in PNS disease remains to be elu-
cidated. This quest has been hampered in the PNS by a
lack of an appropriate model.
Rodents have generally been used as animal models
for the study of nerve degeneration.9,10 Although efficient
in terms of relative ease of experimental manipulation,
rodent models are comparatively poor models for lentivi-
ral-associated sensory neuropathy. Feline immunodefi-
ciency virus (FIV) infection, a lentiviral model of HIV in
cats that causes marked immunosuppression, has been
used occasionally to study the pathogenesis of sensory
neuropathy.5,11,12 Because of the evolutionary distance
between rodents or cats and humans, nonhuman pri-
mates continue to be the most accepted and appropriate
model of lentiviral pathogenesis.13–18 Findings from a
study using a model of pigtail macaques that were
coinoculated with a neurovirulent cloned SIV virus (SIV/
17E-Fr) and an immunosuppressive swarm virus (SIV/
DeltaB670) showed development of multifocal trigem-
inal ganglionitis of varying severity, characterized by
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neuronal loss.19
In the present study, we used a CD8 T-lymphocyte-
depleted (hereafter, CD8-depleted) SIV-infected rhesus
macaque model, which results in the rapid onset of SIV-
associated disease; 77% of persistently (28 days)
depleted macaques develop SIV encephalitis, with a pro-
gression to terminal AIDS within 12 weeks after infection.
This model is highly reproducible and is commonly used
to investigate monocyte/macrophage activation and traf-
fic, peripheral immune responses, and central nervous
system (CNS) disease.20–28 This model has not previ-
ously been examined as a potential model for HIV-SN.
Given the similarities between HIV infection and CNS
disease and SIV encephalitis, we hypothesized that this
rapid model might also be useful for a model of HIV-SN in
humans. The present study aimed to develop a model of
HIV-SN using SIV-infected CD8-depleted rhesus ma-
caques, to aid in understanding of the pathogenic mech-
anisms underlying development of HIV-SN.
Materials and Methods
Animals, Viral Infection, and CD8 Lymphocyte
Depletion
Five cohorts of rhesus macaques (Macaca mulatta) were
used, a total of 15 animals. The first cohort (uninfected,
CD8-depleted; M1 and M2) consisted of two uninfected
control animals that were CD8-depleted by treatment with
a human anti-CD8 antibody administered only once (50
mg/kg i.v.). The human anti-CD8 antibody was provided
by the NIH Nonhuman Primate Reagent Resource.14–17,26,28
The second cohort consisted of three uninfected non-
CD8-depleted control animals (uninfected, non-CD8-de-
pleted; M3 to M5). The third cohort (CD8-depleted; M6 to
M9) consisted of four animals that were inoculated with a
viral swarm SIVmac251 (a generous gift from Ronald
Desrosiers, New England Primate Research Center,
Southborough, MA) and were treated with human anti-
CD8 antibody cM-T807 to achieve rapid disease pro-
gression with a high incidence of SIV encephalitis. These
animals were administered 10 mg/kg s.c. of anti-CD8
antibody at day 6 after infection and 5 mg/kg i.v. at days
8 and 12 after infection. In the CD8-depleted groups,
animals were defined as persistently depleted if the CD8
cells were depleted for28 days. In the present study, all
of the animals were persistently depleted, and CD8 levels
were partially recovered at the time of necropsy in all
animals except M9. Cohort 4 (non-CD8-depleted, rapid
progressors; M10 to M12) consisted of three SIV-infected
animals that were not CD8-depleted and that developed
AIDS within 6 months after infection. Cohort 5 (non-CD8-
depleted, conventional progressors; M13 to M15) con-
sisted of three SIV-infected animals that were not CD8-
depleted and that developed AIDS 1 year after
infection.
To compare only peripheral effects of SIV infection,
animals were selected that developed SIV encephali-
tis, as defined by the presence of multinucleated giantcells and accumulation of parenchymal and perivas-
cular infiltrates of macrophages in the brain.15,16,18,29
All animals were anesthetized with ketamine HCl, eu-
thanized by an intravenous pentobarbital overdose,
and exsanguinated. Animals from cohorts 1 and 3 were
housed at the New England Primate Research Center
(Southborough, MA) and animals from cohorts 2, 4,
and 5 were housed at Tulane University’s National Pri-
mate Research Center (Covington, LA) in strict accor-
dance with standards of the American Association for
Accreditation of Laboratory Animal Care.
Necropsy and Histopathology
Animals were necropsied immediately after death. Rep-
resentative sections of all major organs were collected,
fixed in 10% neutral buffered formalin, embedded in par-
affin, sectioned at 5 m, and stained using H&E. Staining
was performed as follows. Tissues were deparaffinized in
xylene, hydrated in graded alcohols, counterstained with
Harris hematoxylin solution (Sigma-Aldrich, St. Louis,
MO) for 2 minutes, and rinsed with running water. The
slides were then dipped sequentially in acid alcohol (90%
methanol, 5% sulfuric acid, 5% acetic acid; Sigma-Al-
drich) and ammonia water (15 to 20 drops ammonium
hydroxide in 250 mL water; Sigma-Aldrich), with a rinse
under running water after each dip, followed by 80%
alcohol for 2 minutes and then eosin (Sigma-Aldrich) for 2
minutes. Finally, tissue sections were rinsed in graded al-
cohols, dehydrated with xylene, and mounted with Vecta-
Mount medium (Vector Laboratories, Burlingame, CA).
Histopathological Analysis of Dorsal Root
Ganglia Morphology
H&E-stained sections of dorsal root ganglia (DRG) were
evaluated blindly for histopathological lesions by a
board-certified pathologist (A.D.M.); scoring was based
on the presence and severity of infiltrating mononuclear
cells, neuronophagia, and neuronal loss/degeneration.
Ganglionitis was scored as 1, 2, or 3 according to the
following criteria: mild (1), for scattered infiltrating mono-
nuclear cells with rare evidence of neuronophagia and/or
neuronal loss; moderate (2), for increased numbers of
infiltrating mononuclear cells with occasional neu-
ronophagia and/or neuronal loss; and severe (3), for
abundant infiltrating mononuclear cells, frequent neu-
ronophagia, and neuronal loss.
Immunohistochemistry
DRG sections were deparaffinized with xylene, hydrated
in a series of graded alcohols, and stained with a pan-
macrophage marker anti-CD68 (Dako, Carpinteria, CA),
anti-SIV protein p28 (Bartels; Trinity Biotech USA, James-
town, NY), a pan-T-cell marker anti-CD3 (Dako) or anti-
CD8 (Vector Laboratories). Sections were counterstained
with hematoxylin, dehydrated, and mounted using Vecta-
Mount permanent mounting medium (Vector Laborato-
ries). Sections were visualized and photographs taken
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MicroImaging, Thornwood, NY) with Plan-Apochromat
20/0.8 and 40/0.95 Korr objectives. The number of
CD68, viral p28, CD3, and CD8 cells were counted
manually. Data are expressed as a percentage of total
satellite cells, calculated by dividing the number of pos-
itively stained cells by the total number of cells stained
with hematoxylin and multiplying by 100. The absolute
number of cells (positive cells/mm2) was calculated by
dividing the number of positive cells in the field by the
size of the field examined (each 20 field was 0.147
mm2). Cell counts were performed on eight nonoverlap-




was administered 24 hours before necropsy as a slow
bolus injection (60 mg BrdU/kg body weight, i.v.).
Results
Histopathology
Two uninfected CD8-depleted (cohort 1), three unin-
fected non-CD8-depleted (cohort 2), four SIV-infected
CD8-depleted (cohort 3), and six SIV-infected non-CD8-
depleted rhesus macaques (cohorts 4 and 5) were used





Cohort 1: uninfected, CD8-depleted
M1 NA None 13.
M2 NA None 11.
Cohort 2: uninfected, non-CD8-depleted
M3 NA None 15.
M4 NA None 15.
M5 NA None 11.
Cohort 3: SIV-infected, CD8-depleted
M6 2.6 Severe 28.
M7 4.4 Moderate-severe 26.
M8 3.0 Moderate-severe 25.
M9 2.0 Moderate 19.
Cohort 4: SIV-infected, non-CD8-depleted, rapid progressors
M10 3.9 Mild-moderate 38.
M11 5.1 Mild-moderate 27.
M12 2.0 Mild 16.
Cohort 5: SIV-infected, non-CD8-depleted, conventional prog
M13 19.0 Mild-moderate 24.
M14 17.7 Mild 19.
M15 14.2 Mild 10.
Data are expressed as means  SEM. The percentage of positive ce
number of satellite cells (total hematoxylin-positive cells) surrounding the
absolute number of cells was calculated as the cells/mm2 in eight separat
of the field examined (eg, for a 20 field, it was 0.147 mm2).
NA, not applicable.in the present study (Table 1). Of the six SIV-infectednon-CD8-depleted animals, three were rapid progressors
(AIDS progression within 6 months) (non-CD8 depleted:
rapid progressors) and three were conventional progres-
sors (progressed to AIDS 1 year after infection) (non-
CD8 depleted: conventional progressors) (Table 1). DRG
tissue sections from uninfected controls had healthy neu-
rons surrounded by a thin layer of supportive satellite
cells (Figure 1A), regardless of CD8 T-cell depletion sta-
tus. DRG from all CD8-depleted SIV-infected animals re-
vealed variable satellitosis, neuronophagia, and develop-
ment of Nageotte nodules, which are compact areas of
satellite cells that accompany DRG neuronal loss (Figure
1B). Morphological assessment of DRG from non-CD8-de-
pleted infected macaques demonstrated less severe pe-
ripheral neuropathy than that found in CD8-depleted ma-
caques, with three animals having mild lesions and three
animals having mild to moderate DRG pathology (Table 1).
The DRGpathology was similar in nondepleted SIV-infected
animals regardless of whether they were rapid or conven-
tional progressors (Figure 1, C and D).
Immunohistochemistry
To characterize the degree of satellitosis and neu-
ronophagia in the CD8-depleted SIV-infected animals,
sections of DRG tissues were immunostained with an
anti-CD68 monoclonal antibody (Figure 2). In uninfected
CD8-depleted macaques, CD68 immunostaining identi-




1 491.5  20.9 NA NA
07 683.2  74.1 NA NA
569.7  24.0 NA NA
528.9  107.2 NA NA
420.6  64.1 NA NA
1342.0  146.9 8.2  1.4 317.4  51.6
1338.3  72.0 5.0  0.7 216.1  36.7
1292.0  50.8 1.5  0.2 66.8  11.5
814.5  72.0 1.2  0.3 60.1  15.8
1820.9  65.8 4.8  0.8 143.5  49.4
1148.3  231.5 45.6  1.3 1921.8  225.9
663.1  56.8 10.5  3.2 432.1  131.4
s
1095.0  86.4 2.0  0.3 70.3  7.4
833.6  60.2 2.0  0.2 70.0  9.2
560.8  45.4 2.6  0.1 127.1  18.8
(table continues)
calculated as the number of positively stained cells divided by the total
ultiplied by 100. Eight 20 fields were used for each measurement. The
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total satellite cells were CD68 (491.5 and 683.2 CD68
satellite cells/mm2 of tissue, respectively) (Table 1 and
Figure 2A). Immunostaining for CD68 in DRG of the CD8-
depleted SIV-infected macaques revealed a significant




2.6  0.7 101.1  24.0 4.6
6.4  0.7 191.2  21.1 2.0
11.2  1.2 597.6  62.8 10.7
7.0  0.5 293.5  26.6 4.6
8.2  0.8 345.4  27.8 8.4
7.6  1.4 252.6  36.0 1.7
3.6  0.4 134.4  15.4 1.0
3.1  0.4 122.6  8.9 6.2
1.7  0.5 96.3  23.3 0.0
5.7  0.5 266.0  22.7 6.7
4.4  0.9 152.3  30.3 2.4
3.0  0.3 123.3  14.8 0.0
12.1  1.8 513.6  45.2 17.8
5.3  0.6 243.2  23.7 5.1
19.3  4.0 778.0  85.7 13.0with uninfected controls (P 0.05, unpaired t-test) (Table
1). The quantity of CD68 cells in DRG tissue from CD8-
depleted SIV-infected animals ranged from 814.5 to 1342.0
cells/mm2. Activated CD68 macrophages (based on IHC
and morphology) in the CD8-depleted SIV-infected animals




165.0  28.1 13.8  0.7
68.3  9.7 12.7  0.6
236.9  19.5 12.4  0.6
134.7  12.8 10.3  0.8
255.9  26.7 12.3  0.5
57.3  11.8 26.9  1.2
29.9  6.5 23.1  1.5
200.8  28.4 12.9  0.4
0.0  0.0 14.8  0.7
212.0  13.0 11.5  0.7
88.8  17.1 18.7  1.8
0.0  0.0 13.3  0.9
574.2  34.2. 13.2  0.7
253.5  6.8 15.3  1.0
589.9  17.5 11.6  0.6
Figure 1. H&E staining of DRG tissues reveals
neuronophagia and inflammatory infiltrates in
CD8-depleted SIV-infected rhesus macaques. A:
A representative DRG tissue section from an un-
infected rhesus macaque (M1) demonstrates
healthy neurons surrounded by a thin layer of
supportive satellite cells. B: A representative sec-
tion of DRG tissue from a CD8-depleted SIV-
infected rhesus macaque (M8) reveals satellito-
sis, neuronophagia, and the development of
Nageotte nodules (arrow). C: Representative
section of DRG tissue from a non-CD8-depleted
SIV-infected rapid progressor rhesus macaque
(M11) that progressed to AIDS within 6 months.
Representative neuronophagia is indicated by an
arrow. D. Representative section of DRG tissue
from a non-CD8-depleted SIV-infected rhesus ma-
caque that was a conventional progressor (M15).
The DRG pathology is similar in nondepleted SIV-
infected animals, regardless of whether they were
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2B). In the non-CD8-depleted uninfected controls, the pro-
portion of CD68 satellite cells ranged from 11.8% to 15.4%
of total satellite cells; absolute numbers ranged from 420.6
to 569.7 CD68 satellite cells/mm2 of DRG tissue (Table 1).
The CD68 immunostaining in the non-CD8-depleted SIV-
infected groups was more variable between animals, but
both the overall percentage of CD68 satellite cells and the
absolute number of CD68 cells in the DRG tissue were
elevated, compared with uninfected animals (Table 1 and
Figure 2, C and D).
DRG tissue was stained with an anti-SIV p28 antibody
to analyze the number of productively SIV-infected satel-
lite cells and to determine whether productive infection
correlated with DRG pathology (Figure 3). Within the
CD8-depleted SIV-infected animals SIV p28 cells
ranged from 1.2% to 8.2%; absolute numbers of SIV
p28 satellite cells ranged from 60.1 to 317.4 cells/mm2
of DRG tissue (Table 1). In these animals, productively
infected cells were consistently localized to ganglionic
Figure 3. Abundant productive viral replication in DRG of SIV-infected ma
to identify productive replication within the DRG satellite cells. A: Represent
with productively infected cells that were consistently localized to ganglionic
of DRG tissue from a non-CD8-depleted SIV-infected rapid progressor rhesu
SIV p28 immunoreactivity. C: A representative section of DRG tissue from a non-CD8-
very little productive infection in the satellite cells. Scale bars: 20 m.lesions of infiltrating cells and prominent neuronophagia
(Figure 3A). In non-CD8-depleted SIV-infected animals
with rapid disease progression, cells staining positively
for SIV p28 ranged from 4.8% to 45.6%; absolute num-
bers of SIV p28 satellite cells ranged from 143.5 to
1921.8 cells/mm2 of DRG tissue (Table 1 and Figure 3B).
In contrast, there were few productively infected satellite
cells in the non-CD8-depleted SIV-infected animals that
were conventional progressors (2.0% to 2.6% of satellite
cells and the absolute number of cells ranging from 70.0
to 127.1 cells/mm2 of DRG tissue staining positively for
SIV p28) (Table 1 and Figure 3C).
To examine the presence of T cells in DRG tissue and
their possible role in DRG inflammation or in controlling
SIV replication, sections of DRG tissue were immuno-
stained with an anti-CD3 antibody. In the two CD8-de-
pleted uninfected animals, the basal level of CD3 T cells
in the DRG tissue was 101.1 and 191.2 cells/mm2, with
2.6% to 6.4% of the satellite cells expressing CD3 (Table
1). In the SIV-infected CD8-depleted animals, the number
Figure 2. Elevated numbers and activation of
CD68 macrophages in the DRG of a CD8-de-
pleted SIV-infected macaque. To characterize
the degree of satellitosis and macrophage acti-
vation in the CD8-depleted SIV-infected animals,
sections of DRG tissues were immunostained
with an anti-CD68 monoclonal antibody. A: A
tissue section from a representative uninfected
rhesus macaque (M2) DRG with CD68 immuno-
reactivity identifies a resident macrophage pop-
ulation diffusely around the DRG neurons. B: A
representative section of DRG tissue from a CD8-
depleted SIV-infected rhesus macaque (M6)
demonstrates prominent cell processes and in-
creased CD68 reactivity. C: Representative sec-
tion of DRG tissue from a non-CD8-depleted
SIV-infected rhesus macaque that was a rapid
progressor (M10) with increased CD68 immune
reactivity, compared with control. D: Represen-
tative section of DRG tissue from a non-CD8-
depleted conventional progressor SIV-infected
rhesus macaque (M13) with a moderate increase
in CD68 reactivity, compared with control. Scale
bars: 20 m.
IHC was performed on DRG tissue sections using an anti-SIV p28 antibody
ction of DRG tissue from a CD8-depleted SIV-infected rhesus macaque (M6)
f infiltrating cells and prominent neuronophagia. B: A representative section
ue (M11) that progressed to AIDS within 6 months demonstrates abundantcaques.
ative se
lesions o
s macaqdepleted conventional progressor SIV-infected rhesus macaque (M14) shows
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compared with uninfected controls. The percentage of
CD3 T cells of total satellite cells ranged from 1.7% to
7.4% and the absolute number ranged from 96.3 to 252.6
CD3 cells/mm2 of DRG tissue (Table 1). In the non-CD8-
depleted uninfected animals, the basal number of CD3
T cells in the DRG tissue was slightly higher than the
CD8-depleted animals, ranging from 293.5 to 597.6 cells/
mm2, with 7.0% to 11.2% of the satellite cells expressing
CD3 (Table 1). In the SIV-infected CD8-depleted animals,
the quantity of CD3 T cells in the DRG tissues was not
significantly elevated in the rapid progressors, compared
with non-CD8-depleted uninfected animals. The percent-
age of CD3 T cells in the total satellite cells in the
conventional progressors was higher than in the unin-
fected animals, ranging from 5.3% to 19.3%; the absolute
number ranged from 243.2 to 778.0 CD3 cells/mm2 of
DRG tissue (Table 1).
To assess the possible role or roles that CD8 T cells
may have in either controlling SIV replication or in pro-
moting inflammatory response in DRG tissue during SIV
peripheral neuropathy, we examined the number of
CD8 T cells present in the DRG tissue. In the CD8-
depleted animals, both uninfected and infected, there
was a similar range (0.0% to 6.2%) of total satellite cells
that were CD8 (Table 1). There were more CD8 cells in
DRG of the non-CD8-depleted animals (5.1% to 17.8% of
total satellite cells), with the greatest number in the con-
ventional progressors (Table 1).
Correlations
We found a positive correlation between the degree of
DRG histopathology and the number of activated CD68
macrophages. Of the four CD8-depleted SIV-infected an-
imals, M6 had the most severe pathology and the great-
est percentage of CD68 satellite cells (severe DRG
pathology with 28.1% CD68 satellite cells). M7 and M8
had moderate to severe DRG damage, with 26.1% and
24.4% CD68 satellite cells, respectively. M9 had mod-
erate DRG pathology, with 19.1% CD68 satellite cells.
Of the six animals in the non-CD8-depleted SIV-in-
fected groups, those with mild DRG damage (M12,
M14, and M15) had lower percentages of CD68 sat-
ellite cells (16.1%  0.8, 19.6%  1.4, and 10.6% 
0.3, respectively) than those with moderate DRG pa-
thology (M10, M11, and M13; 38.0%  1.6, 27.3% 
3.2, and 24.5%  1.2, respectively) (Table 1). This
trend did not hold true across all animals. Overall,
CD8-depleted SIV-infected animals had the most se-
vere pathology, but not the highest percentage of
CD68 satellite cells.
To determine whether there is an accumulation of sat-
ellite cells around DRG neurons, total satellite cells were
counted in H&E-stained sections; this total was divided
by the number of neurons per section of tissue. In the
uninfected control animals, the number of satellite cells
ranged from 10.3 to 13.8 cells per DRG neuronal body
(Table 1). Only two animals, both of them CD8-depleted
SIV-infected, had a significantly increased number of
satellite cells, compared with uninfected animals, with26.0  1.2 and 23.1  1.5 cells per DRG neuronal body.
BrdU labeling showed that 1% of the satellite cells in
CD8-depleted uninfected animals were BrdU, whereas
in CD8-depleted SIV-infected animals the percentage of
BrdU satellite cells ranged from 1.5% to 5% 24 hours
after the BrdU bolus (data not shown). These data dem-
onstrate that, in this model, macrophages traffic from
bone marrow and accumulate around the DRG neurons
within 24 hours after the BrdU bolus, which is increased
during SIV-SN.
Discussion
With the present study, we have developed and charac-
terized a CD8-depleted SIV-infected rhesus macaque
model of SIV-SN. Using this model, we found that satellite
cell activation and recruitment are critical components of
DRG pathology. This rapid-progression model accurately
resembles the peripheral nerve pathology evidenced in
non-CD8-depleted SIV-infected animals with AIDS, but
results in a higher incidence of SIV encephalitis in the
CNS and more severe DRG pathogenesis. It is therefore
an accurate and valuable model for elucidating the
pathogenic mechanism or mechanisms of HIV-SN and
consequent future treatment modalities.
In HIV infection, DRG are a site of neuronal damage,
which is associated with reactive mononuclear phago-
cytes and HIV-infected macrophages. Increasingly, re-
ports from human studies highlight the possible con-
tribution of satellite cell activation and dorsal root
inflammation to the persistence of pathological pain in
peripheral neuropathy via activation of the sensory
pathways that propagate peripheral signals back into
the spinal cord and brain.30,31 Our observations of
morphological and IHC alterations in satellite cells
within the DRG of SIV-infected CD8-depleted ma-
caques recapitulates lesions of sensory neuropathy in
a shorter time frame of AIDS progression: 3 to 4 months
in CD8-depleted macaques, compared with 10 years
in humans and 1 year in conventional progressor
nondepleted macaques. Moderate to severe DRG pathol-
ogy was found in the SIV-infected CD8-depleted ma-
caques, which was characterized by abundant infiltration of
mononuclear cells and subsequent formation of Nageotte
nodules, thus substantiating the observation that neuronal
loss occurs in the DRG of SIV-infected macaques. Consis-
tent with these data, another report described trigeminal
ganglionitis with neuronal loss and neuronophagia in SIV-
infected pigtail macaques.19
An endogenous resident population of scattered
CD68 macrophages is located within tissue of unin-
fected animals and is unchanged by CD8 T cell depletion
itself in the absence of SIV infection. In infected animals,
CD68 macrophages increased in number, surrounded
neuronal bodies, and accumulated in distinct foci (rather
than being dispersed evenly throughout the tissue), sug-
gesting a role for activated satellite cells in perhaps ini-
tiating neuronophagia. These activated cells exhibited
more prominent cell processes and extensive contact
1368 Burdo et al
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hanced phagocytic function. The phagocytic activation of
macrophages presumably occurs in an attempt to com-
bat the underlying viral infection and to clear degenerate
neuronal residue.
The DRG pathology observed in the CD8-depleted
animals was more severe than in the non-CD8-depleted
SIV-infected animals, as measured by satellitosis and
frequency of neuronophagia, whether the animals were
conventional or rapid progressors, suggesting that CD8
T cells may play a role in protecting DRG neurons from
damage. However, CD8 T cell numbers were elevated
in the DRG only of the conventional progressors, and
numbers in the rapid progressors were similar to those in
the CD8-depleted animals, indicating that the CD8 T
cells are not likely to be solely responsible for protecting
the DRG neurons from damage. In addition, for examin-
ing the number of CD3 T cells and subtracting the
number of CD8 T cells, we predict that the few remain-
ing cells are likely to be CD4 T cells in the DRG. (CD4
IHC is not reliable in rhesus macaque paraffin tissue
sections, because of low antigenicity, so we used a pan-
T-cell marker against CD3.) The non-CD8-depleted ani-
mals with mild to moderate peripheral neuropathy gener-
ally had more productively infected satellite cells,
compared with the CD8-depleted SIV-infected animals,
including M6 (with severe DRG pathology), supporting
the idea that productive infection of satellite cells is not a
prerequisite nor is directly related to DRG damage. Of
note, both of the non-CD8-depleted animals with the
highest numbers of productively infected satellite cells
were rapid progressors, so increased productive infec-
tion cannot be explained by a longer time progression to
AIDS but may be explained in terms of the quantity of
CD8 cells. The greatest numbers of CD8 T cells were
found in the animals with the lowest numbers of produc-
tively infected cells.
To compare only peripheral effects of SIV infection with
known CNS pathology, we selected animals that devel-
oped SIV encephalitis. As common as multinucleated
giant cells are to CNS pathology in SIV encephalitis, we
found no multinucleated giant cells present in the sensory
ganglia examined from the same animals. Although sim-
ilarities exist between the CNS and PNS with regard to
SIV-associated pathologies, there are likely fundamental
differences between the pathogenic mechanisms in the
two affected areas, due in part to differences between the
blood-brain barrier of the CNS and the blood-neural bar-
rier of the PNS, as well as to the capacity of PNS neurons
(but not CNS neurons) for extensive regeneration.
We conclude that with a more rapid progression to
AIDS and typically a higher severity of peripheral neurop-
athy, the CD8-depleted SIV-infected rhesus macaque
can serve as a valuable model for studying the patho-
genesis of HIV-induced PNS disease. In this model, ac-
tivation of endogenous CD68 macrophages plays sub-
stantial roles in perpetuating DRG damage and neuronal
loss, as characterized by frequent neuronophagia and
formation of Nageotte nodules.Acknowledgments
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